Also known as: Masimo
Masimo is an American health technology company that develops patient monitoring devices, non-invasive sensors, and related software for hospital and home settings. Founded in 1989 and headquartered in Irvine, California, it has also participated in consumer audio and wearable segments. The company trades on Nasdaq under MASI.
Thermo Fisher posted 10% revenue growth in Q2 and raised guidance; Danaher's Q1 revenue missed but EPS beat. Danaher cited bioprocessing and life sciences strength and expects growth to accelerate.
New rankings from WIPR and IAM Patent 1000 recognize top US patent firms and lawyers, highlighting expertise in pharmaceutical litigation, tech disputes, and strategic portfolio management amid shifting PTAB procedures and rising NPE campaigns in life sciences.
Anterior raised $40M to accelerate health plan AI adoption, bringing total funding to $64M. Other deals include Findhelp's $250M investment, Grow Therapy's $150M Series D, and Bexorg's $23M Series A.
Danaher agreed to acquire Masimo for $9.9 billion, paying $180 per share to expand its diagnostics portfolio into blood oxygen monitoring and patient monitoring devices. Danaher also launched nearly €3 billion in senior notes to help fund the deal, which is expected to close by the second half of 2026.
Danaher approved a $0.40 quarterly dividend and completed a $9.9 billion Masimo acquisition to expand into patient monitoring, while its Life Sciences segment operating profit fell 57% in 2025 to $520 million.
The UK and US announced a pharmaceuticals agreement featuring zero tariffs and a 25% increase in UK spending on innovative medicines. Major pharma M&A deals and regulatory reforms are reshaping the industry in early 2026.
